Scarica l'app Stockscreener
0.00
100.00%
-3.41
Precedente Chiudi:
$3.41
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$524.82M
Reddito:
$117.10K
Utile/perdita netta:
$-161.61M
Rapporto P/E:
0.00
EPS:
-2.4059
Flusso di cassa netto:
-
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$6.30
Opthea Limited Adr Stock (OPT) Company Profile
Nome
Opthea Limited Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta OPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OPT
Opthea Limited Adr
|
0.00 | 524.82M | 117.10K | -161.61M | 0 | -2.4059 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Opthea Limited Adr Stock (OPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-03-25 | Downgrade | Jefferies | Buy → Underperform |
| 2025-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-03-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-12-08 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-26 | Iniziato | SVB Leerink | Outperform |
| 2020-11-17 | Iniziato | Citigroup | Buy |
| 2020-11-11 | Iniziato | Oppenheimer | Outperform |
| 2020-11-11 | Iniziato | SVB Leerink | Outperform |
| 2020-11-11 | Iniziato | Truist | Buy |
Mostra tutto
Opthea Limited Adr Borsa (OPT) Ultime notizie
Millennium Management LLC Reduces Stock Holdings in Opthea Limited (NASDAQ:OPT) - Defense World
Citadel Advisors LLC Takes $79,000 Position in Opthea Limited (NASDAQ:OPT) - Defense World
Opthea Limited (NASDAQ:OPT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail
Opthea Limited (NASDAQ:OPT) Given Average Rating of “Hold” by Analysts - Defense World
Sarepta Therapeutics (SRPT) Gets a Buy from Oppenheimer - The Globe and Mail
Brokerages Set Opthea Limited (NASDAQ:OPT) PT at $1.33 - Defense World
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Opthea Ltd shares corporate update in SEC filing - Investing.com
Opthea Halts Wet AMD Clinical Trials By Investing.com - Investing.com South Africa
Opthea Halts Wet AMD Clinical Trials - Investing.com
Opthea Limited (NASDAQ:OPT) Receives $1.33 Consensus PT from Brokerages - Defense World
Hold Rating Issued for Opthea Limited Amid Uncertainty Following Phase 3 Trial Failure - TipRanks
Opthea Limited: Hold Rating Amid Phase 3 Trial Failure and Financial Uncertainty - TipRanks
Opthea’s COAST Phase 3 Trial Fails to Meet Primary Endpoint, Raising Financial Concerns - TipRanks
Opthea COAST trial misses primary endpoint, enters talks with DFA Investors - TipRanks
Opthea reports phase 3 trial results for eye treatment - Investing.com
Promising Developments and Strong Financial Position Propel AbSci’s Growth Prospects - TipRanks
Opthea Limited Announces New Securities Quotation on ASX - TipRanks
Opthea Limited Reports Increased Losses Amid Clinical Advancements - TipRanks
Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment - TipRanks
Opthea reports mid-year financial results - Investing.com
Opthea Ltd completes key drug product campaign - Investing.com
Opthea Completes Key Phase 3 Trial Milestone in Wet AMD Treatment - TipRanks
Opthea Limited completes week 52 patient visits in the COAST trial - Ophthalmology Times
Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position - TipRanks
Opthea to Present at Oppenheimer Healthcare Conference - GlobeNewswire Inc.
OPTOpthea Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Is Opthea Limited (OPT) One of the Best ASX Stocks to Buy According to Hedge Funds? - Insider Monkey
Opthea Unveils Promising Wet AMD Therapy at Investor Day - TipRanks
Why Opthea (OPT) Is Among the Best Australian Stocks to Buy Now? - Yahoo Finance
Jane Street Group LLC Invests $114,000 in Opthea Limited (NASDAQ:OPT) - Defense World
Opthea’s Innovative Approach to AMD Treatment with Sozinibercept - TipRanks
Opthea to Host Investor Days in New York and Australia - The Manila Times
Opthea Sets Key 2025 Investor Events to Showcase Breakthrough Wet AMD Treatment Sozinibercept - StockTitan
Opthea Limited Reports Earnings Results for the Half Year Ended December 31, 2024 - Marketscreener.com
Opthea to Present Phase 3 Trial Update at J.P. Morgan Healthcare Conference - TipRanks
Race Oncology bolsters leadership - The Australian
Opthea Highlights Innovative Wet AMD Therapy - TipRanks
Opthea CEO to Present at Citi Healthcare Conference, Spotlights Eye Disease Treatment - StockTitan
Opthea Limited Targets AMD Market with Sozinibercept - TipRanks
Opthea Appoints Kathy Connell to Board of Directors - The Manila Times
Opthea's Wet AMD Program Featured at Ophthalmology Events - The Manila Times
Is Opthea Limited (OPT) the Penny Stock with the Biggest Upside Potential According to Analysts? - Yahoo Finance
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025 - The Manila Times
Opthea Limited Announces Chief Financial Officer Changes -October 07, 2024 at 05:52 pm EDT - Marketscreener.com
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 - StockTitan
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept - Stock Titan
Opthea Limited Adr Azioni (OPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):